BREAST CANCER.
Information on current developments in both regular and alternative or complementary treatments and resources for breast cancer at all stages.
Browse alphabetical list by subject or use search box above using keywords.
Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
If you want to support us you can do so through a donation: See registration OPS
General: Obesity increases risk of breast cancer metastasis and significantly increased risk of death from breast cancer by 38%, shows large Danish population. Article posted December 20, 2010
December 20, 2010: Source: J Clin Oncol. November 1929, 2010
A breast cancer patient who is overweight has a higher risk of breast cancer spread to other organs in the body and also a greater risk of dying from her breast cancer. The thicker one is the greater the risk. On average, the risk to 48% within 30 years to die of breast cancer. This shows a large population in Denmark over a period of 30 years. And the higher the BMI, the greater the risk of death related to breast cancer. the effect of treatment, whether chemotherapy or hormone therapy is the thicker one is proportionately less. It is therefore important to do something about obesity. Here the figures from the study put together.
High BMI Increases Risk for Metastasis and Death
In the current study, Marianne Ewertz, MD, DMSc, from the Department of Oncology, Odense University Hospital in Denmark, and colleagues, used the Danish Breast Cancer Cooperative Group to identify 53,816 women Treated for early-stage breast cancer in Denmark Between 1977 and 2006. These patiënten all had complete follow-up information for first event (loco-regional recurrences and distant metastases) up to 10 years, and mortality data up to 30 years.
Within this group, information on BMI at diagnosis was available for 18,967 (35%) patients. The cohort was Divided Writing 4 categories, According To BMI: Less than 25 kg / m 2, 25 to 29 kg / m 2, 30 + kg / m 2, and unknown.
Patients with a BMI of 30 kg / m 2 or Greater tended to be older, more Were Often postmenopausal, had larger tumors, and had lymph nodes removed Both more and more positive lymph nodes, but had less deep fascia Writing invasion (P <. 001 for all), compared with Those with a BMI or Less Than 25 kg / m 2.
Estimated at a median potential follow-up period of 7.1 years, 4180 Were there locoregional recurrences and distant metastases as first event 7278. Although BMI did not Seem to Influence the risk for locoregional recurrences, distant metastases for risk rose with Increasing BMI. At 10 years, the cumulative incidences Were
- 20.1% (95% confidence interval 2,079,702,307, 19.2% - 20. 9%) for Patient with a BMI or Less Than 25 kg / m 2,
- 22.4% (95% CI, 21.1% - 23.8%) for Patient with a BMI of 25 to 29 kg / m 2, and
- 24.3% (95% CI, 22.1% - 26.5%) for Patient with a BMI of 30 kg / m 2 or more.
That the authors noted among the group of Patients Whose BMI was unknown, the risk of distant metastases Developing throughout the 10 years of follow-up was consistently lower: At 10 years, the cumulative incidence was 16.1% (95% CI, 15.6% - 16.6%).
At a median potential follow-up or EstimatedRunTime 11.4 years, 15.197 patiënten had died of breast cancer, and 5967 had succumbed to Other Causes. There was a trend of Increasing risk for breast cancer-specific mortality with Increasing BMI. At 30 years, the cumulative risks of dying from breast cancer Were
- 46.4% (95% CI, 44.8% - 48.0%) for Patient with a BMI or Less Than 25 kg / m 2,
- 53.4% (95% CI, 50.5% - 56.2%) for Patient with a BMI of 25 to 29 kg / m 2, and
- 57.2% (95% CI, 51.8% - 62.2%) for Patient with a BMI of 30 kg / m 2 or more.
Those with unknown BMI consistently had a lower risk of dying from breast cancer, the cumulative risk at 30 years was 41.1% (95% CI, 40.2% - 42.0%). The risk for death from Other Causes was higher among patiënten Also with the greatest BMI compared with Those in the Other weight categories.
The authors Also Evaluated the efficacy of adjuvant treatment in lean and obese women. Although They did not observe a specific pattern consistently the first 10 years of follow-up, Both chemotherapy and endocrine therapy seemed to be less effective in patient with BMIs of 30 kg / m 2 or Greater or more after 10 years.
The authors have disclosed no relevant financial relationships.
J Clin Oncol. Published online November 29, 2010.
